Status:
UNKNOWN
Cancer Fusion Hybrids and Desmoplasia
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Health Research Institutes, Taiwan
Conditions:
Fusion Protein Expression
Bone Marrow Cells
Eligibility:
All Genders
Brief Summary
Clinical and preclinical evidence reveal that cancer cells may fuse with hematopoietic cells to obtain properties including migration, proliferation and drug resistance. The investigators hypothesize ...
Detailed Description
Desmoplasia has been shown to exert mechanical forces and create a biochemical intra-tumoral immunity and influence the development and progression of a malignancy. Recent reports suggest a significan...
Eligibility Criteria
Inclusion
- prospective
- normal peripheral blood laboratory results within one week.
- hematopoietic cell growth factors are allowed for peripheral blood stem cell donors.
- hyperemia patients. .
- age 20 to 70.
- retrospective
- recipient of bone marrow transplantation and developed malignant tumor after transplantation.
- tumor was resected or biopsied and preserved in Pathology Department. 4-8um thick, 10 slices.
Exclusion
- prospective
- malignant cancer patients with no recurrent disease for less than 5 years
- major cardiovascular disease, immnologic disease, pregnancy.
- long term users of immuno-suppressants and steroids.
- retrospective
- (1)none.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 10 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05399719
Start Date
May 25 2022
End Date
March 10 2025
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Cancer Research, National Health Research Institutes
Miaoli, Taiwan, 35053